Orocidin and Bio-Convert expects to begin pilot efficacy studies in 2025

Rhea-AI Summary

Nordicus Partners (OTCQB:NORD) has announced that its wholly-owned subsidiaries, Orocidin A/S and Bio-Convert ApS, plan to initiate pilot efficacy studies in 2025. These studies will focus on patients with periodontitis and oral leukoplakia. The company clarified that both subsidiaries are currently in the preclinical phase, correcting information provided in previous press releases.

Positive

• Advancement to clinical phase planned for 2025 with pilot efficacy studies

Negative

• Correction of previous misleading information about development stage
• Both subsidiaries still in preclinical phase, indicating earlier stage than previously suggested

BEVERLY HILLS, California, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB:NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in providing Nordic and U.S. life sciences companies with optimal conditions to establish themselves on the U.S. market, today announced that its two wholly-owned subsidiaries, Orocidin A/S (“Orocidin”) and Bio-Convert ApS (“Bio-Convert”), expect to begin pilot efficacy studies in patients with periodontitis and oral leukoplakia in 2025. As of today both Orocidin and Bio-Convert are preclinical phase biopharmaceutical companies, which was incorrectly stated in previous press releases.

About Nordicus Partners Corporation

Nordicus Partners Corporation specializes in providing Nordic and U.S. life sciences companies with the best possible conditions to establish themselves on the U.S. market, taking advantage of management’s combined +90 years of experience in the corporate sector, serving in different capacities both domestically and globally. Nordicus’ core competencies lie in assisting Danish as well as other Nordic and U.S. companies in different areas of corporate finance activities, such as: business- and market development, growth strategies, attracting the right people, partners and capital for businesses and company acquisitions and sales. In May 2024 Nordicus bought 95% of the Danish company, Orocidin A/S, a preclinical-stage biopharmaceutical company which is advancing the next generation of periodontitis therapies. In November 2024 Nordicus bought 100% of the Danish company, Bio-Convert ApS, a preclinical-stage biopharmaceutical company focused on revolutionizing the treatment of oral leukoplakia and also in November Nordicus bought the remaining 5% of Orocidin A/S.

For more information about Nordicus, please visit: www.nordicuspartners.com

Forward-Looking Statements

The Company believes that this press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Terms such as “may,” “might,” “would,” “should,” “could,” “project,” “estimate,” “pro-forma,” “predict,” “potential,” “strategy,” “anticipate,” “attempt,” “develop,” “plan,” “help,” “believe,” “continue,” “intend,” “expect,” “future,” and terms of similar import (including the negative of any of these terms) may identify forward-looking statements. Such forward-looking statements, including but not limited to statements regarding the plans and objectives of management for future operations, are based on management’s current expectations and are subject to risks and uncertainties that could cause results to differ materially from the forward-looking statements. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the accuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, market acceptance of the company’s products and services; competition from existing products or new products that may emerge; the implementation of the company’s business model and strategic plans for its business and our products; estimates of the company’s future revenue, expenses, capital requirements and need for financing; current and future government regulations; and developments relating to the company’s competitors. Readers are cautioned not to place undue reliance on forward-looking statements because of the risks and uncertainties related to them. For further information on such risks and uncertainties, you are encouraged to review the Company’s filings with the Securities and Exchange Commission (“SEC”), including its Annual Report on Form 10-K for the fiscal year ended March 31, 2024 and its Quarterly Reports on Form 10-Q for the fiscal quarters ended June 30, 2024 and September 30, 2024. The Company assumes no obligation to update any forward-looking statements as a result of new information or future events or developments, except as required by law.

For further information contact:

Mr. Henrik Rouf
Chief Executive Officer
Phone +1 310 666 0750
Email hr@nordicuspartners.com

Investor Relations
Jonathan Paterson
Harbor Access Investor Relations
Jonathan.Paterson@Harbor-Access.com
Tel +1 475 477 9401

FAQ

When will Nordicus (NORD) begin pilot efficacy studies for periodontitis and oral leukoplakia?

Nordicus (NORD) expects to begin pilot efficacy studies through its subsidiaries Orocidin and Bio-Convert in 2025.

What is the current development stage of Nordicus (NORD) subsidiaries Orocidin and Bio-Convert?

Both Orocidin and Bio-Convert are currently in the preclinical phase of development.

What medical conditions will Nordicus (NORD) target in their 2025 pilot studies?

The pilot efficacy studies will target patients with periodontitis and oral leukoplakia.

What correction did Nordicus (NORD) make regarding its subsidiaries' development status?

Nordicus corrected previous press releases by clarifying that both Orocidin and Bio-Convert are in the preclinical phase, not in a more advanced stage as previously stated.